Laroze Partners · Analysis · Healthcare & Life Sciences · September 2026

In most countries, a subsidiary general manager drives commercial performance. In France, they first and foremost manage a regulatory and economic equation whose timeline and rules they do not control. This specificity changes the nature of the mandate, and it should change the way we recruit for this position. Here is what this role actually entails, how the system in which it operates works, and what needs to be evaluated before making an appointment.

The numbers to know

Why this topic matters now

Three deadlines converge at the end of 2026. The framework agreement governing relations between the Economic Committee for Health Products (CEPS) and the industry expires on September 30, the date on which the social security financing bill for 2027 is presented to the Council of Ministers. This budget is the last one before the presidential election, in a context where the National Health Insurance recommends 3.9 billion euros in savings and identifies pharmaceuticals as the primary target.

In addition to this national pressure, there is an external constraint. Price agreements signed in the United States by twenty-six laboratories, covering nearly 89% of the brand-name drug market, index US prices to the lowest prices charged in developed countries. Consequently, every price negotiated in France becomes a reference that impacts the most profitable market in the world, which has already led to a noticeable decline in European launches.

A France general manager now stands at the intersection of these two pressures, and their ability to balance them determines a substantial portion of the value created by their subsidiary.

How drug pricing actually works in France

Understanding the mandate requires understanding the system. The pharmaceutical market does not operate like a standard market, since the prescriber decides, the patient consumes, and the National Health Insurance pays, which justifies public price regulation.

Evaluation by the French National Authority for Health (HAS)

Prior to any economic negotiation, the Transparency Committee evaluates the product based on two distinct criteria. The actual therapeutic benefit (SMR) determines whether the drug will be reimbursed and at what rate. The improvement in actual therapeutic benefit (ASMR), graded from I to V, measures the clinical progress compared to existing treatments.

This second criterion conditions everything else, as the ASMR level defines the negotiation framework to which the laboratory will be entitled. A strong ASMR opens the door to a protected European price for several years. A weak ASMR leads to a comparison with existing comparators, which is often unfavorable.

Negotiation with the CEPS

The Economic Committee for Health Products (CEPS) is an interministerial body that sets or negotiates the price of reimbursable medicines, both in retail pharmacies and hospitals. Every year, it receives a ministerial guidance letter that frames its policy, and it negotiates by taking into account the HAS evaluation, projected sales volumes, real-world conditions of use, as well as the setup of manufacturing sites on French territory.

This last criterion is worth highlighting, as it makes industrial localization an economic negotiation argument, and therefore a general management matter.

The distinction between list price and net price

This is where the function takes on its most technical dimension. The list price is the public price, published in the Official Journal, and is the only price known to everyone. The price actually received by the laboratory is a net price, obtained after applying confidentially negotiated rebates.

These rebates take multiple forms: volume clauses that cap sold quantities, clauses related to daily treatment costs, first-pack discounts, and rebates linked to early access schemes. Their weight has exploded over the past decade, rising from 2.2% of gross revenue in 2013 to 19.5% in 2023, and continuously exceeding 10% since 2020.

A leader who thinks in terms of list price does not understand the real economics of their portfolio. The performance of their subsidiary is decided in an area that does not appear on any public document.

Global regulation mechanisms

Beyond the price of each individual product, several mechanisms control overall expenditure. The annual program of price cuts is systematically applied. The safeguard clause imposes a collective contribution when expenditure exceeds the threshold voted by Parliament, and its yield was estimated at approximately 1.7 billion euros in March 2025.

The joint report by the General Inspectorate of Social Affairs (IGAS) and the General Inspectorate of Finance (IGF) published in May 2026 makes a clear assessment: the safeguard clause is no longer an exceptional regulatory tool; it has become a yield mechanism triggered every year under conditions of economic uncertainty for businesses. The 2026 financing law initiated a reform aimed at restoring it as an instrument of last resort, offsetting it with an increase in the tax on revenue, which is deemed more predictable.

For a subsidiary leader, this development means that the financial predictability of their business depends on decisions made outside their company, and that a portion of their annual results is decided in the National Assembly.

What this system implies for the mandate

A general manager for France in the pharmaceutical industry therefore performs a function whose structure differs significantly from that of their counterparts in other markets.

Their key stakeholder is not a client but a government administration. The growth of their portfolio depends less on their sales force than on the outcome of negotiations conducted with the CEPS, and their commercial room for maneuver is exercised within a scope set by public authorities.

Their decision horizon is twofold. They must deliver an annual plan to headquarters while dealing with a regulatory calendar that follows its own logic, where a price negotiation, a tariff revision, or a budget debate can shift several margin points.

Their position within the group is unique. Since international indexing mechanisms came into effect, a price granted in France no longer impacts only France. The leader must therefore defend the value of a national launch to headquarters, at a price level that does not damage the global equation, which means influencing portfolio trade-offs even before negotiating with French authorities.

Finally, their role includes an active institutional dimension. Trade association positions, relations with health authorities, industrial footprint decisions, and supply commitments are an integral part of the job, directly influencing the quality of upcoming negotiations.

The skills that determine success

This configuration calls for a profile whose qualities cannot be read on a conventional commercial curriculum vitae.

Mastery of market access. Understanding HAS and CEPS mechanics, knowing how to build an economic case, and anticipating the impact of an ASMR level on a product's entire lifecycle. This skill is acquired through practice, rarely through training.

Reading public dynamics. Identifying the logics of the administrations involved, distinguishing a negotiating position from a fundamental direction, and anticipating the effects of a budget bill before its adoption. This is a political skill in the noble sense, exercised without partisan bias.

Internal influence capacity. Convincing foreign headquarters that a highly constrained market deserves investment, defending a launch sequence, and obtaining resources for a country whose apparent profitability is lower than others. Many leaders who excel externally fail specifically on this front.

Long-term endurance. A price negotiation is measured in quarters and an institutional relationship in years. A leader who changes stance with every budget cycle loses the credibility that makes them valuable to authorities.

Scientific and ethical solidity. Public and hospital stakeholders evaluate a company's credibility through that of its leader. A purely commercial discourse closes doors permanently.

The most frequent hiring mistakes

Three configurations recur regularly and should be identified prior to appointment.

The first consists in recruiting a purely commercial profile, brilliant in execution and team performance, but lacking market access experience. This leader discovers after a few months that their usual levers have no effect, and attributes to market conditions what is actually a failure to read the system.

The second is transferring a leader from a free market, where prices are set by competition. Adjustment requires time that most value-creation plans do not account for.

The third, more subtle, is recruiting an excellent market access technician without verifying their ability to lead, make trade-offs, and carry weight within a global organization. Regulatory expertise alone does not make a leader.

How to evaluate this profile before appointing

Evaluation must focus on the junction of three dimensions that track record alone does not reveal.

The economic dimension is verified by examining how the candidate reasons on net price rather than list price, and how they integrate rebates and regulatory mechanisms into their reading of performance.

The institutional dimension is assessed by the quality and seniority of their relationships within the ecosystem, as well as their understanding of their public interlocutors' constraints, not just their own.

The managerial dimension is measured by their ability to engage a team in an environment where victories are slow and where structural decisions are partially out of the company's control.

These three dimensions rarely overlap in a single profile, which explains the scarcity of the talent pool and the need for a search conducted through direct approach, across a scope that extends beyond the pharmaceutical industry alone.

Frequently asked questions

Must a France Pharma GM come from market access? Not necessarily, but they must master its logic. A profile from commercial or operations can succeed if they have already worked in a regulated pricing environment and know how to surround themselves with experts. However, a complete lack of exposure to these mechanisms carries a high risk.

How long does it take for a leader to be operational in this market? Technical understanding can be acquired in a few months. Institutional credibility, which conditions the quality of negotiations, generally takes two to three years. This is a strong argument in favor of stability and proactive succession planning.

Should a French profile be prioritized? Nationality matters less than system knowledge and integration into the ecosystem. A foreign leader who has worked in France for several years can be perfectly legitimate, provided their ability to influence headquarters offsets their cultural distance from the administrative landscape.

What is the primary indicator of success at twelve months? Rarely revenue, the evolution of which depends largely on prior decisions. Useful signals are the quality of submitted dossiers, the outcome of initiated negotiations, the solidity of established institutional relationships, and a demonstrated ability to secure favorable decisions from headquarters.

Key takeaways

Appointing a general manager for France in the pharmaceutical industry means designating the person who will represent the company's position before public authorities, in a system where prices are negotiated, where a growing share of revenue is paid back in rebates, and where the economic framework is redefined annually by law.

This mandate is as much a negotiation mandate as a management mandate. Treating it as a commercial role leads to hiring mistakes whose cost is measured in lost years of market access, impacting the entire portfolio.

Drug prices are negotiated. Negotiators are recruited.

Article written by Thomas Rozier, Founder — Executive search firm Laroze Partners, Healthcare & Life Sciences. Executive recruitment, succession planning, and leadership team securing, in France and internationally.

Sources: Economic Committee for Health Products (CEPS) · National Authority for Health (HAS) · Leem · IGAS and IGF joint report on drug price regulation, May 2026 · National Health Insurance, proposals for 2027 · Paris Dauphine University PSL. This article reflects the practitioner perspective of Laroze Partners.